First Drug In Japan For Alcoholism Enters Phase III Trials
This article was originally published in PharmAsia News
Executive SummaryJapan's first drug to treat alcohol dependence has been placed in Phase III trials by its developer, Nippon Shinyaku. The Japanese company is marketing the acamprosate drug under license from Merck's Swiss drug company, Serono International. The drug is marketed in the United States as Campral, whose U.S. approval was gained by Forest Laboratories. Nippon Shinyaku is counting on Health Ministry approval in time to begin marketing it in 2013. (Click here for more - a subscription may be required
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.